Novel food: Clostridium butyricum TO-A
- Food safety
- Novel/traditional foods
Summary
The European Union (EU) has authorised the use of the novel food Clostridium butyricum TO-A in food supplements intended for the general population above 3 years of age, excluding pregnant and lactating women, when specific maximum levels are not exceeded.
EU authorises use of novel food Clostridium butyricum TO-A
Commission Implementing Regulation (EU) 2025/2233 of 6 November 2025 authorising the placing on the market of Clostridium butyricum TO-A as a novel food and amending Implementing Regulation (EU) 2017/2470.
Update
The European Union (EU) has authorised the use of the novel food Clostridium butyricum TO-A in food supplements intended for the general population above 3 years of age, excluding pregnant and lactating women, when specific maximum levels are not exceeded.
What is changing?
The EU has authorised the use of Clostridium butyricum TO-A as a novel food in food supplements intended for the general population above 3 years of age, excluding pregnant and lactating women.
Food supplements containing C. butyricum TO-A must not exceed the maximum levels specified for each age group (see Table 1).
Food supplements that contain C. butyricum TO-A must include in their labelling:
- “Clostridium butyricum TO-A”
- a statement of the age groups that should not consume these supplements, depending on the consumers targeted:
- pregnant and lactating women
- infants and children under 3, 10, or 14 years of age
- infants, children, and adolescents under 18 years of age.
Only the company that applied for authorisation, TOA Biopharma Co. Ltd, is authorised to sell this novel food on the EU market over the next 5 years, unless they permit marketing by other companies, or if another company obtains a novel food authorisation without making reference to scientific data protected by TOA Biopharma Co. Ltd.
Why?
The European Food Safety Authority (EFSA 2025) has concluded that the novel food Clostridium butyricum TO-A is safe when used in food supplements intended for the general population above 3 years of age, excluding pregnant and lactating women, when not exceeding specific maximum levels.
Timeline
This novel food may be placed on the EU market from 27 November 2025.
Background
Clostridium butyricum TO-A is a bacterium with the TO-A strain, deposited under number FERM BP-10866.
This Regulation updates the Annex to Regulation 2017/2470 which lists authorised novel foods (see the Union list of novel foods). For further information on the EU novel foods authorisation process, see Novel foods explained.
Resources
EFSA (2025) Safety of Clostridium butyricum TO-A as a novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal, 23: e9371.
Regulation 2017/2470 establishing the Union list of novel foods.
Regulation 2015/2283 on novel foods.
Sources
Commission Implementing Regulation (EU) 2025/2233 authorising the placing on the market of Clostridium butyricum TO-A as a novel food and amending Implementing Regulation (EU) 2017/2470.
Tables & Figures
Source: based on Regulation 2025/2233
Disclaimer: Under no circumstances shall COLEAD be liable for any loss, damage, liability or expense incurred or suffered that is claimed to have resulted from the use of information available on this website or any link to external sites. The use of the website is at the user’s sole risk and responsibility. This information platform was created and maintained with the financial support of the European Union. Its contents do not, however, reflect the views of the European Union.
EU authorises use of novel food Clostridium butyricum TO-A
Commission Implementing Regulation (EU) 2025/2233 authorising the placing on the market of Clostridium butyricum TO-A as a novel food and amending Implementing Regulation (EU) 2017/2470.
What is changing and why?
The European Union (EU) has authorised the novel food Clostridium butyricum TO-A for use in food supplements intended for the general population above 3 years of age, excluding pregnant and lactating women, when it does not exceed specific maximum levels (see Table 1). Specific labelling requirements apply.
Only the company that applied for authorisation, TOA Biopharma Co. Ltd, is authorised to sell this novel food on the EU market over the next 5 years, unless they permit marketing by other companies, or if another company obtains a novel food authorisation without making reference to scientific data protected by TOA Biopharma Co. Ltd.
Timeline
This novel food may be placed on the EU market from 27 November 2025.
Tables & Figures
Source: based on Regulation 2025/2233
Disclaimer: Under no circumstances shall COLEAD be liable for any loss, damage, liability or expense incurred or suffered that is claimed to have resulted from the use of information available on this website or any link to external sites. The use of the website is at the user’s sole risk and responsibility. This information platform was created and maintained with the financial support of the European Union. Its contents do not, however, reflect the views of the European Union.